Zentalis Pharmaceuticals, Inc. to Post Q1 2025 Earnings of ($0.71) Per Share, Wedbush Forecasts (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Research analysts at Wedbush issued their Q1 2025 earnings estimates for shares of Zentalis Pharmaceuticals in a research note issued on Tuesday, May 7th. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of ($0.71) for the quarter. Wedbush has a “Neutral” rating and a $15.00 price target on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($3.72) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.73) EPS and Q4 2025 earnings at ($0.61) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.91. The company had revenue of $40.56 million during the quarter, compared to the consensus estimate of $35.00 million. During the same period last year, the firm posted ($1.07) EPS.

Several other brokerages also recently commented on ZNTL. Stifel Nicolaus decreased their target price on shares of Zentalis Pharmaceuticals from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday. HC Wainwright dropped their target price on shares of Zentalis Pharmaceuticals from $46.00 to $40.00 and set a “buy” rating for the company in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Zentalis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.14.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock opened at $12.43 on Thursday. Zentalis Pharmaceuticals has a one year low of $9.56 and a one year high of $31.46. The business’s 50 day simple moving average is $13.70 and its two-hundred day simple moving average is $13.43. The stock has a market capitalization of $882.65 million, a P/E ratio of -2.74 and a beta of 1.82.

Institutional Trading of Zentalis Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Eventide Asset Management LLC increased its stake in Zentalis Pharmaceuticals by 47.9% during the 4th quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after purchasing an additional 3,745,936 shares in the last quarter. Vanguard Group Inc. raised its holdings in Zentalis Pharmaceuticals by 6.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock worth $105,047,000 after acquiring an additional 307,490 shares during the last quarter. Federated Hermes Inc. boosted its stake in Zentalis Pharmaceuticals by 10.9% during the 4th quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock valued at $32,733,000 after purchasing an additional 212,872 shares during the last quarter. Decheng Capital LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter worth $31,809,000. Finally, Wellington Management Group LLP increased its holdings in shares of Zentalis Pharmaceuticals by 0.5% in the 3rd quarter. Wellington Management Group LLP now owns 1,917,105 shares of the company’s stock worth $38,457,000 after purchasing an additional 8,661 shares in the last quarter.

Insiders Place Their Bets

In other news, CFO Melissa B. Epperly sold 2,573 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $11.44, for a total transaction of $29,435.12. Following the sale, the chief financial officer now owns 451,449 shares in the company, valued at approximately $5,164,576.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 6.10% of the stock is owned by corporate insiders.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.